Bentley Pharmaceuticals Engages Sharon Merrill Associates.- Nationally Recognized Investor Relations Investor relations The process by which the corporation communicates with its investors. and Corporate Communications Corporate communications is the process of facilitating information and knowledge exchanges with internal and key external groups and individuals that have a direct relationship with an enterprise. Firm Retained to Enhance Investment Community Visibility - EXETER, N.H. -- Bentley Pharmaceuticals, Inc. (NYSE NYSE See: New York Stock Exchange : BNT BNT Bentley Pharmaceuticals, Inc. (stock symbol) BNT Boston Naming Test (psychology) BNT Bermuda National Trust BNT Bulgarian National TV BNT Broadband Network Termination BNT Binary File Transfer ), a specialty pharmaceutical company, announced today it has engaged Sharon Merrill Associates, Inc. to support its investor relations and corporate communications efforts. Based in Boston, Sharon Merrill Associates (SMA (1) See SMA connector. (2) (Shared Memory Architecture) See shared video memory. (3) (Software Maintenance Association) A membership organization that began in 1985 and ended in 1996. ) is a nationally recognized investor relations and corporate communications consulting firm Noun 1. consulting firm - a firm of experts providing professional advice to an organization for a fee consulting company business firm, firm, house - the members of a business organization that owns or operates one or more establishments; "he worked for a . Richard P. Lindsay, chief financial officer Bentley Pharmaceuticals, commented, "We are at an important juncture in our company's evolution and we are excited to have SMA on board to help us communicate our story. We are steadily growing our established and profitable generic pharmaceuticals business, while advancing our promising drug delivery business. We look forward to partnering with SMA to enhance the investment community's understanding of Bentley Pharmaceuticals." "Effective communications with Wall Street is a critical success factor for any public company, particularly one with an emerging story like Bentley," said Maureen T. Wolff-Reid, Sharon Merrill Associates president. "Bentley's management team is dedicated to broadening the company's visibility with investors. We welcome the opportunity to leverage our firm's 20-plus years of investor relations experience in helping them achieve this objective." Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and generic pharmaceutical products. Bentley's proprietary drug delivery technologies enhance the absorption of pharmaceutical compounds across various membranes. Bentley manufactures and markets a growing portfolio of generic and branded generic pharmaceuticals in Europe for the treatment of cardiovascular, gastrointestinal, infectious and central nervous system diseases through its subsidiaries -- Laboratorios Belmac, Laboratorios Davur, Laboratorios Rimafar and Bentley Pharmaceuticals Ireland. Bentley also manufactures and markets active pharmaceutical ingredients through its subsidiary, Bentley API. Additional information regarding Bentley Pharmaceuticals may be obtained through Bentley's web site at www.bentleypharm.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: This press release contains forward looking statements, including without limitation, statements regarding the prospects for Bentley's generic pharmaceutical business and its drug delivery business. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from future results expressed or implied by such statements. Factors that may cause such differences include, but are not limited to, risks associated with the following: clinical trials, the timing and nature of regulatory approvals, changes in third-party reimbursement and government mandates that impact pharmaceutical pricing, development and commercialization of Bentley's proprietary products and formulations, competition from other manufacturers of generic and proprietary pharmaceuticals, intellectual property litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. , the efficacy and safety of Bentley's products, the unpredictability of patent protection, international operations, and other uncertainties detailed under "Risk Factors" in Bentley's most recent Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. and its other subsequent periodic reports filed with the Securities and Exchange Commission. Bentley cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and Bentley undertakes no obligation to update or revise the statements, except as may be required by law. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion